
[Expand/Collapse all sections]Expand all

This document outlines details of the previous Pharmaceutical Benefits
Scheme (PBS) subsidised idelalasib for patients with chronic lymphocytic
leukaemia (CLL) and small lymphocytic lymphoma (SLL).

This procedure is no longer current. Chronic lymphocytic leukaemia and
Small lymphocytic lymphoma Program was moved to the general schedule on
01 January 2022. This page will be removed in approximately 1 month.
Contact Operational.Blueprint to request historical content.

                                   

-   Services Australia ABN 90 794 605 008 
